Answers are grounded in this paper and cite their sources.
Research on the reproductive toxicity of Calotropis procera (C. procera) (Oshar) and abamectin on test animals indicates that the two drugs exhibit high levels of antifertility, with abamectin having endocrine and gonadal effects. C. procera extracts are bioactive and can induce organ-specific toxicity, hormonal imbalances, and dose-dependent adverse effects; hence, the need to develop standardized extracts. Antiandrogenic properties of latex and root extracts have demonstrated significant inhibitory effects on androgen activity, potentially interfering with androgen receptor signaling and reducing testosterone-mediated physiological functions, including complete induction of implantation in female rats when subjected to a specific dosage of Oshar extract. Exposure to abamectin can disrupt reproductive hormones by elevating follicle-stimulating hormone, luteinizing hormone, and prolactin and altering testosterone homeostasis and inducing oxidative and nitrosative stress, ultimately resulting in poor fertility. Additional evidence shows that the developmental toxicity and gametogenesis malady may occur with abamectin even at lower doses relative to maternal toxicity; the no-observed-adverse-effect level (NOAEL) in mammals has been determined as low as 0.1 mg/kg/day. The two agents exhibit quite dissimilar forms of reproductive toxicity jointly, implying standardized doses, research of their mechanism of action, and more extensive reproductive testing.
No takes yet. Share an insight, caveat, or question.
El-Arably et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: